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Objective: We sought to assess the safety and efficacy of transmyocardial
revascularization combined with coronary artery bypass grafting in
patients not amenable to complete revascularization by coronary bypass
alone. Methods: A total of 263 patients whose standard of care was coro-
nary artery bypass grafting and who had one or more ischemic areas
not amenable to bypass grafting were prospectively randomized to
receive coronary bypass of suitable vessels plus transmyocardial revas-
cularization to areas not graftable (n = 132) or coronary bypass alone
with nongraftable areas left unrevascularized (n = 131). Group preop-
erative demographics and operative characteristics were similar.
Results: The operative mortality rate after coronary bypass/transmyo-
cardial revascularization was 1.5% (2/132) versus 7.6% (10/131) after
coronary bypass alone (P = .02). Patients undergoing both coronary
bypass and transmyocardial revascularization required less postopera-
tive inotropic support (30% vs 55%, P = .0001) and had a trend toward
fewer insertions of intra-aortic balloon pumps (4% vs 8%, P = .13) than
did patients having coronary bypass alone. Multivariable predictors of
operative mortality were coronary artery bypass alone (odds ratio, 5.3;
95% confidence interval, 1.1-25.7; P = .04) and increased age (odds
ratio, 1.1; 95% confidence interval, 1.0-1.2; P = .03). One-year Kaplan-
Meier survival (95% vs 89%, P = .05) and freedom from major adverse
cardiac events defined as death or myocardial infarction (92% vs 86%,
P = .09) favored the combination of coronary bypass and transmyocar-
dial revascularization. Baseline to 12-month improvement in angina and
exercise treadmill scores was similar between groups. Conclusions: In a
prospective, randomized, multicenter trial, transmyocardial revascular-
ization combined with coronary artery bypass grafting in patients not
amenable to complete revascularization by coronary bypass alone was
safe; however, angina relief and exercise treadmill improvement were
indistinguishable between groups at 12 months of follow-up. Operative
and 1-year survival benefits observed after adjunctive transmyocardial
revascularization require confirmation by a larger validation study,
which is ongoing. (J Thorac Cardiovasc Surg 2000;119:540-9)
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I ncomplete revascularization after coronary arterybypass grafting (CABG) occurs in up to 25% of
patients and adversely affects freedom from late car-
diac events.1-4 In one series only the presence of dis-
eased but nongrafted arteries significantly influenced
event-free survival, as defined by the absence of death,
recurrent angina, myocardial infarction (MI), and the
need for repeat CABG.3
In 4 prospective randomized trials, transmyocardial
revascularization (TMR) significantly improved angina
compared with continued medical therapy5-8 when used
as the sole therapy to treat ischemic heart disease not
amenable to CABG or percutaneous transluminal coro-
nary angioplasty (PTCA). Considering the success of
TMR as a sole therapy, we hypothesized that in patients
with one or more target areas not amenable to grafting,
CABG plus TMR (CABG/TMR) would be safe and
result in decreased adverse cardiac events. Several non-
randomized studies with adjunctive TMR have been
reported.9-12 This summary reports the findings at 1
year of follow-up of a single-blinded, prospective, ran-
domized, multicenter trial designed to assess the safety
and efficacy of CABG/TMR in patients who would be
incompletely revascularized by CABG alone.
Patients and methods
Patient selection. Between October 1996 and October
1997, 266 patients at 24 US centers (see Appendix) whose
standard of care was CABG but who had one or more viable
target areas served by vessels not amenable to CABG were
prospectively identified.
The institutional review boards of each participating center
and the Food and Drug Administration (FDA) approved the
study, which was monitored by a blinded independent data
and safety committee. Informed consent was obtained from
each patient.
Inclusion criteria were isolated coronary artery disease
with one or more major vessels or branches not bypassable
for anatomic reasons (distal or diffuse disease) and the pres-
ence of viable myocardium surrounding the nonbypassable
vessels. Exclusion criteria were as follows: severe chronic
obstructive pulmonary disease (forced expiratory volume in 1
second < 55% of predicted value); non–Q-wave or Q-wave
MI within 2 or 3 weeks of enrollment, respectively; severe
arrhythmia uncontrolled by a device or medication; and
decompensated cardiac failure.
Randomization. A total of 266 patients were prospective-
ly randomized to receive either CABG alone or CABG of
suitable vessels plus TMR of areas not amenable to grafting.
Randomization occurred before surgery and was computer
generated and stratified by sex and ejection fraction (EF; ≤
40% > 40%). Patients were blinded for 1 year after surgery as
to whether they received adjunctive TMR. After randomiza-
tion, 3 patients were identified as having violated protocol
and were excluded from further analyses. Protocol violations
included 2 patients randomized to CABG alone (1 patient
received CABG/TMR for compassionate reasons and 1
patient received an unanticipated concomitant mitral valve
replacement), and 1 patient was randomized to CABG/TMR
and withdrew from the study before surgery. Therefore, for
study purposes, 132 patients received CABG/TMR, and 131
patients received CABG alone. The two treatment groups had
similar demographics, including predicted operative mortali-
ty rates determined by Parsonnet13 risk modeling (Table I).
Study end points. Study end points included the follow-
ing: operative and 1-year all-cause mortality rates; require-
ment for postoperative left ventricular support; 30-day and 1-
year major adverse cardiac events defined as death or MI;
angina class assessment; exercise treadmill scores; and the
need for repeat interventions (PTCA or CABG).
Baseline data and follow-up. Baseline data, in addition to
patient demographics, included the following: EF determined
by radionuclide ventriculography, echocardiography, or car-
diac catheterization; angina class determination, according to
Canadian Cardiovascular Society definition; and a symptom-
limited modified Bruce exercise treadmill test. Patients
unable to perform a baseline exercise treadmill test because
of angina (n = 83) were assigned values of zero minutes and
one metabolic equivalent (MET).
Patients underwent clinical follow-up at 3-, 6-, and 12-
month intervals after surgery. At each interval, patients were
evaluated for major adverse cardiac events, angina class, and
occurrence of repeat CABG, PTCA, or both. A modified
Bruce exercise treadmill test was obtained at 12 months for
comparison with baseline values.
Follow-up for operative mortality rates and 30-day and 1-
year major adverse cardiac events was 100% (263/263),
Table I. Patient demographics and baseline cardiac
characteristics
CABG/TMR CABG alone 
(n = 132) (n = 131) P value*
Mean age (y) 64 ± 10† 63 ± 10† .4
Preoperative EF (%) 51 ± 13† 50 ± 14† .4
Male, % (n) 73 (96) 72 (94) .9
Diabetes, % (n) 51 (65) 40 (51) .10
Previous MI, % (n) 43 (57) 47 (62) .6
Previous CABG, % (n) 20 (26) 20 (26) 1.0
Cerebrovascular disease, 13 (16) 9 (12) .6
% (n)
Prior peripheral vascular 12 (16) 18 (23) .2
surgery, % (n)
Renal dialysis, % (n) 5 (7) 5 (6) 1.0
Predicted mortality,‡ % 6.3 (7) 6.6 (8) .8§
(expected no. of deaths)
*Statistical differences of qualitative variables determined by using the Fisher
exact test and differences in continuous variables determined by using a 2-
sample t test.
†Mean ± SD.
‡Parsonnet risk modeling.
§Wilcoxon 2-sample test.
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100% (263/263), and 89% (235/263), respectively. Paired
baseline and 12-month exercise treadmill tests were avail-
able for comparison in 55% (135/243) of patients. Angina
assessment was complete at 3, 6, and 12 months on 86%
(215/250), 79% (195/247), and 84% (204/243) of patients,
respectively.
Operative procedure. The CABG procedure and postop-
erative care were center specific and not different between
groups within each center. Patients randomized to CABG
alone had viable target areas which were served by vessels
not amenable to grafting left untreated. Patients randomized
to receive adjunctive TMR had CABG performed on suitable
vessels and TMR channels placed every square centimeter in
viable areas unable to be grafted.
Adjunctive TMR was performed by using a 20-W pulsed
holmium:yttrium-aluminum-garnet (holmium) laser (Eclipse
Surgical Technologies, Sunnyvale, Calif). Laser energy was
delivered with a flexible 1-mm optical fiber. Laser calibra-
tions were set to deliver 6 to 8 W of laser energy at 5 pulses/s;
typically, 3 to 8 pulses were required to traverse the
myocardium. Laser energy application was controlled with a
foot switch and not gated to the cardiac cycle. In this series
adjunctive TMR was performed while patients were receiving
cardiopulmonary bypass (CPB). TMR was performed either
on an arrested heart before placement of grafts (n = 19) or
after the completion of grafts (n = 112). Median laser time
was 6 minutes (5th percentile, 3 minutes; 95th percentile, 12
minutes) during which an average of 25 ± 10 channels were
created.
Statistical analysis. All statistical analyses were carried
out by using SAS software (SAS Institute, Inc, Cary, NC).
Demographic and baseline variables were analyzed by using
a 2-sample t test for continuous variables and the χ2, Fisher
exact, or Cochran-Mantel-Haenszel tests for qualitative vari-
ables. A goodness-of-fit test was used to compare predicted
versus actual operative mortality rates within each treatment
group. Differences in operative mortality rates and adverse
events between groups were determined by using the Fisher
exact test. Kaplan-Meier survival estimates were used to ana-
lyze mortality rates at 1 year, as well as freedom from major
adverse cardiac events (death and MI) at 30 days and 1 year.
Statistical differences in Kaplan-Meier survival estimates
were determined by using the Wilcoxon-Gehan test. The Cox
method of multivariate logistic regression was used to deter-
mine predictors of operative mortality and to determine pre-
dictors of 1-year freedom from mortality, MI, or severe angi-
na (class III or IV). Variables used for these analyses were as
follows: prior CABG, diabetes, sex, age, treatment arm, pre-
operative EF of 35% or greater or less than 35%, and the
presence of endarterectomies.
The distribution of angina classes for each group at base-
line and each follow-up interval was analyzed by using the
Cochran-Mantel-Haenszel test. Differences between groups
in the proportions of patients in each angina class were deter-
mined by using the Fisher exact test.
Net change from baseline to 12 months in exercise tread-
mill test duration and METs were calculated for each patient.
Differences between groups were analyzed with a 2-sampled
t test.
Results
Morbidity and mortality. The operative characteris-
tics of both groups were similar with respect to CPB
time, number and distribution of bypassed vessels, and
number of patients having endarterectomies (Table II).
Operative mortality (in-hospital or 30-day) after
CABG/TMR was 1.5% (2/132) compared with 7.6%
(10/131) after CABG alone (P = .02). Operative deaths
after CABG/TMR were cardiac related in one patient
and caused by multisystem organ failure in another.
Operative deaths after CABG alone were cardiac relat-
ed in 7 patients, with one death each from renal insuf-
ficiency, pulmonary embolism, and cerebral vascular
accident. Operative deaths were distributed randomly
among enrollment centers. The actual operative mortal-
ity rate observed in the group undergoing CABG alone
was similar to the Parsonnet predicted mortality rate
(7.6% vs 6.6%, respectively; P = .5). In contrast, the
actual operative mortality rate in the CABG/TMR
Table II. Operative characteristics
CABG/TMR CABG alone 
(n = 132) (n = 131) P value*
Time on bypass 99 ± 65† 98 ± 52† .9
No. of vessels bypassed 3.1 ± 1.2† 3.4 ± 1.2† .07
Coronary arteries grafted
Left anterior descending 89 (117) 88 (115) .9
artery, % (n)
Circumflex artery, % (n) 55 (72) 63 (83) .17
Right coronary 73 (97) 77 (101) .6
artery, % (n)
Endarterectomy, % (n) 9 (12) 8 (11) 1.0
No. of laser channels 25 ± 10†
*Statistical differences of qualitative variables determined by using the Fisher
exact test and differences in continuous variables determined by using a t test.
†Mean ± SD.
Table III. Multivariable regression analysis of risk
factors for operative mortality (n = 263)
95% CI
Variable Odds ratio Lower Upper P value
Treatment group 5.3 1.1 25.7 .04
(CABG alone)
Age 1.1 1.0 1.2 .03
Female sex 0.6 0.2 2.6 .5
Diabetes 0.6 0.2 2.3 .4
Prior CABG 0.6 0.2 2.8 .6
EF ≥ 35% vs <35% 1.7 0.3 9.1 .6
Endarterectomy 0.3 0.1 1.5 .15
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group trended lower than the predicted rate (1.5% vs
6.3%, P = .06). The need for postoperative left ventric-
ular support was less after CABG/TMR. Postoperative
inotropic support was used in fewer patients undergo-
ing CABG/TMR compared with those undergoing
CABG alone (30% [39/132] vs 55% [72/131], P =
.0001). In addition, a trend toward fewer intra-aortic
balloon pumps after CABG/TMR was also observed
(4% [5/132] vs 8% [11/131], P = .13). Multivariable
predictors of operative mortality (Table III) were
CABG alone (odds ratio, 5.3; 95% confidence interval
[CI], 1.1-25.7; P = .04) and increased age (odds ratio,
1.1; 95% CI, 1.0-1.2; P = .03). At 1 year, Kaplan-Meier
intent-to-treat survival estimates (95% vs 89%, P = .05)
were better after CABG/TMR than after CABG alone
(Fig 1).
Postoperative complications were similar in both
groups (Table IV). Postoperative hemorrhage requiring
re-exploration occurred in 4 patients after CABG/TMR
and 1 patient after CABG alone. Laser channels were
the source of the hemorrhage in 2 patients who required
re-exploration for bleeding after CABG/TMR. In both
cases laser channels had been created after CABGs
were completed and just before terminating CPB.
Currently, the preferred method for performing adjunc-
tive TMR is on an arrested heart just after initiating
CPB. Adjunctive TMR when performed on an arrested
heart alleviates the concern for intraoperative arrhyth-
mias, allows channels to be placed more quickly, and
may reduce bleeding when compared with laser chan-
nels placed at the conclusion of CPB.
Major adverse cardiac events, angina evaluation,
and exercise treadmill tests. Kaplan-Meier freedom
from major adverse cardiac events (death and MI) was
significantly enhanced after CABG/TMR at 30 days
when compared with CABG alone (97% vs 91%, P =
.04). At 1 year, however, freedom from major adverse
cardiac events was similar (92% vs 86%, P = .09)
between patients receiving CABG/TMR and CABG
Fig 1. One-year Kaplan-Meier intent-to-treat survival estimates.
Table IV. Operative complications (in-hospital or at
30 days)
CABG/TMR CABG alone 
(n = 132) (n = 131) P value*
Atrial arrhythmia, % (n) 18 (24) 16 (21) .7 
Ventricular fibrillation, % (n) 4 (5) 2 (3) .7
Congestive heart failure, 5 (6) 6 (8) .6
% (n)
Cerebral vascular accident, 1 (1) 2 (3) .4
% (n)
Reoperation for bleeding, 3 (4) 1 (1) .4
% (n)
MI
Q wave, % (n) 2 (2) 0 (0) .5
Non-Q wave, % (n) 1 (1) 2 (2) .6
*Statistical differences determined by using the Fisher exact test.
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alone. Both groups experienced significant angina
improvement at 3, 6, and 12 months of follow-up com-
pared with baseline values. Patients undergoing
CABG/TMR tended to have less class III and IV angi-
na at 12 months when compared with patients under-
going CABG alone (4.7% [5/106] vs 11.2% [11/98], P
= .11); however, overall angina class distribution was
similar between groups at each follow-up interval (Fig
2). The only multivariable predictor of death, MI, or
severe class III or IV angina 1 year after surgery was
CABG alone (odds ratio, 2.2; 95% CI, 1.1-4.3; P = .03;
Table V).
Both groups experienced significant improvements
in exercise treadmill test duration and METs. The
paired difference between baseline and 12-month val-
ues for each group revealed that the net change in exer-
cise time (6.1 ± 5.4 vs 5.6 ± 6.8 minutes, P = .7) and
METs (3.9 ± 3.4 vs 3.6 ± 3.7 minutes, P = .9) was sim-
ilar between patients who received CABG/TMR versus
those who received CABG alone.
Additional cardiac procedures aimed at treating angi-
na were required in 3 patients during follow-up. Two
patients, one from each group, underwent subsequent
PTCA; one patient randomized to CABG alone under-
went subsequent TMR with a carbon dioxide laser and
ultimately underwent cardiac transplantation.
Discussion
Transmyocardial revascularization with both a
holmium and carbon dioxide laser has received FDA
approval for use as sole therapy to treat patients with-
out options with class III and IV angina. In 4 prospec-
tive, randomized, surgical trials, angina relief after
TMR was significantly better than that after continued
medical therapy.5-8 The safety and efficacy of TMR
combined with CABG in patients who would be
incompletely revascularized by CABG alone have been
more difficult to assess because of the influence of
adjacent bypass grafts and lack of randomized control
arms in previous studies.9-12 In this single-blinded,
prospective, randomized, multicenter trial, patients
who received CABG/TMR had reduced operative and
1-year mortality rates, required less postoperative left
ventricular support, and experienced enhanced 30-day
freedom from major adverse cardiac events when com-
pared with CABG alone. However, at 1-year follow-up,
Fig 2. Mean angina class at baseline (2.8 vs 2.9, P = .5) was similar between patients undergoing CABG/TMR
and those undergoing CABG alone. Three months after the surgery, both groups experienced a similar significant
reduction in angina class (0.4 vs 0.4, P = 1.0). At 12 months of follow-up, angina class remained significantly
improved and was similar between groups (0.5 vs 0.6, P = .2).
Table V. Multivariable regression analysis of risk factors
for death, MI, and severe angina (class 3 and 4) at 12
months (n = 263)
95% CI
Variable Odds ratio Lower Upper P value
Treatment group 2.2 1.1 4.3 .03
(CABG alone)
Age 1.0 1.0 1.0 .5
Female sex 0.6 0.3 1.3 .2
Diabetes 0.8 0.4 1.6 .5
Prior CABG 0.6 0.3 1.2 .16
EF ≥ 35% vs <35% 1.3 0.5 3.7 .6
Endarterectomy 0.5 0.2 1.6 .3
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freedom from major adverse cardiac events, angina
relief, and improvement in exercise treadmill duration
and METs were similar between groups.
The early benefits observed after CABG/TMR must
be analyzed in the context of potential study limita-
tions. Randomization for this study occurred preopera-
tively. Even if randomization had occurred intraopera-
tively, the surgeon’s belief in TMR could influence
surgical conduct and bias decisions regarding whether
a vessel was bypassable. In an attempt to achieve as
complete a revascularization as possible in the group
undergoing CABG alone, surgeons might increase the
operative mortality rate by performing more technical-
ly questionable grafts or more endarterectomies.
Because surgeons cannot be blinded, this limitation is
difficult to circumvent in any adjunctive TMR trial. In
this study, however, operative characteristics were sim-
ilar between groups; there were no obvious differences
between groups with regard to time on bypass, number
of vessels bypassed, distribution of coronary arteries
grafted, or number of endarterectomies performed
(Table II). Furthermore, the operative mortality rate in
the group undergoing CABG alone was similar to the
mortality rate predicted by using Parsonnet risk model-
ing. The operative mortality rate observed in the group
undergoing CABG alone may be perceived as exces-
sive in light of the patients’ well-preserved left ventric-
ular function, but the predicted operative mortality rate
in both groups reflects the significant comorbidities
commonly associated with diffuse coronary artery dis-
ease. Participants in this study were not ideal candi-
dates for CABG because the diffuse nature of their
coronary artery disease limited complete conventional
revascularization. The diffuse nature of their coronary
artery disease is emphasized by the use of endarterec-
tomies in 9% (23/263) of patients in this series. As
determined by using Parsonnet risk modeling, the actu-
al mortality rate in the control group was similar to the
predicted mortality rate (7.6% vs 6.6%, P = .5). By
contrast, the operative mortality rate after CABG/TMR
tended to be less than the predicted rate (1.5% vs 6.3%,
P = .06). Multivariable predictors for operative mortal-
ity rate in this series were CABG alone and increased
age.
The early benefits of adjunctive TMR observed in
this trial are similar to results seen in previous animal
studies, which suggested TMR channels were acutely
patent. Sen and colleagues14,15 reported improved sur-
vival and reduced MI size after mechanical acupunc-
ture and left anterior descending artery ligation in dogs.
Mirhoseini and Cayton16 reproduced Sen’s study but
used a carbon dioxide laser to create transmural chan-
nels. The 83% survival of dogs treated with TMR and
acute left anterior descending ligation contrasted
sharply with the fatal outcomes observed in all dogs
treated with left anterior descending ligation alone.
Horvath and associates,17 using a carbon dioxide laser,
observed reduced MI size and improved regional con-
tractility after TMR in an acute ischemic ovine model.
They attributed the benefits of TMR to patent laser
Fig 3. Ventriculography done immediately after percutaneous myocardial revascularization demonstrating blood
flow in laser channels (arrows) created in the anterior distribution. (Reprinted with permission from Perin EC,
Dohmann HJF, Dorhmann HFR, Mattos ND, Carvalho LA. Laser channels after percutaneous transmyocardial
revascularization. Circulation 1999;99:2218.) 
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channels, which were verified histologically. Endo-
cardial laser revascularization in dogs has also demon-
strated preservation of myocardial function during
acute ischemia, which was attributed to improved
nutritive perfusion through laser channels.18 More
recently, acute channel patency after percutaneous
myocardial revascularization in human subjects has
been demonstrated with ventriculography (Fig 3).19
In contrast, other investigators,20,21 using micro-
spheres, have been unable to demonstrate perfusion
through acute laser channels. Kohmoto and col-
leagues22 confirmed the conduction of blood through
laser channels created in dogs for up to 2 weeks before
closure but concluded that the amount of perfusion
through these channels would not have physiologic sig-
nificance. That conclusion was based on the assump-
tion that channel blood flow was 1-way from the left
ventricle to the myocardial capillary network, rather
than in a to-and-fro pattern.
Long-term benefits regarding angina and exercise tol-
erance are more difficult to assess after CABG/TMR
because of the strong positive influence of bypass graft-
ing on both groups. As expected, both groups experi-
enced significantly improved angina and exercise tread-
mill test scores at 12 months compared with baseline
values. Although patients undergoing CABG/TMR
tended to have less class III or IV angina at 12 months
of follow-up (P = .11), overall angina class distribution
and exercise treadmill scores were similar between
groups. When TMR was used as sole therapy, a signifi-
cant improvement (>1.5 minutes) in exercise treadmill
duration was observed when compared with medical
therapy alone.6 As bypass grafts deteriorate, longer fol-
low-up will determine whether adjunctive TMR slows
the inevitable return of angina for patients not com-
pletely revascularized by CABG alone.
The mechanism of TMR remains controversial.
Compelling theories include laser energy–induced
angiogenesis,23,24 sympathetic denervation,25,26 and
laser channel patency.16,17,27 The mechanism may be
multifaceted and may be influenced by the presence of
adjacent bypass grafts.
In this prospective, randomized, multicenter trial,
TMR combined with CABG in patients who were not
amenable to complete revascularization by CABG
alone was observed to be safe. The operative and 1-
year survival benefits observed after adjunctive TMR
require confirmation by a larger validation study, which
is ongoing.
We thank John Quiring, PhD, for statistical analysis of the
data.
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Appendix
Enrollment sites, principal investigators, and the number of
patients contributed (in parentheses).
Central Baptist Hospital, Lexington, Ky, S. P. Saha, MD (10)
Cooper Hospital, Camden, NJ, A. J. DelRossi, MD (39)
Deborah Heart and Lung, Browns Hill, NJ, G. Laub, MD,
M. Grosso, MD (4)
Fairfax Hospital, Falls Church, Va, E. A. Lefrak, MD (20)
Hoag Hospital, Newport Beach, Calif, D. Zusman, MD (1)
Huntington Hospital, Los Angeles, Calif, V. Starnes, MD (4)
University of Louisville Hospital and Jewish Heart and Lung
Institute, Louisville, Ky, R. D. Dowling, MD (16)
Kaiser Permanente Medical, Los Angeles, Calif, T. A. Pfeffer,
MD (16)
Lankenau Hospital, Wynnewood, Pa, S. Goldman, MD (7)
Maimonides Hospital, Brooklyn, NY, M. W. Connolly, MD (5)
North Ridge Hospital, Fort Lauderdale, Fla, H. Dennis, MD (10)
Phoenix Memorial Hospital, Phoenix, Ariz, J. Hessel, MD (5)
Redding Medical Center, Redding, Calif, F. Realyvasquez, MD
(39)
Sacred Heart Hospital, Spokane, Wash, S. L. Selinger, MD (1)
Sentara Norfolk General Hospital, Norfolk, Va, S. Szenptetery,
MD (12)
St Francis Hospital, Beach Grove, Ind, D. Raess, MD (5)
St John’s Hospital, Springfield, Ill, J. Schneider, MD (8)
St Joseph’s Hospital, Atlanta, Ga, D. Murphy, MD (2)
St Patrick’s Hospital, Missoula, Mont, C. M. G. Duran, MD (2)
St Vincent Hospital, Indiana Heart Institute, Indianapolis, Ind,
K. B. Allen (21)
St Vincent’s Medical Center, Jacksonville, Fla, M.
Mostovych, MD (10)
Sutter Memorial Hospital, Sacramento, Calif, D. Schuch,
MD (12)
Terrebonne General Medical Center, Houma, La, T. L. Fudge,
MD (11)
Washington Hospital Center, Washington, DC, S. Boyce, MD
(3)
Discussion
Dr O. Howard Frazier (Houston, Tex). This is a prospec-
tive, randomized, controlled, blinded, multicenter study,
which did show statistical improvement in the perioperative
mortality rate, as well as a suggestion of improvement in
long-term angina benefit and exercise tolerance. Both of
these modalities, energy modalities, have been approved as
sole therapy by the FDA in randomized prospective studies
compared within medically managed patients.
I am pleased, in spite of early work to the contrary pre-
sented by those using the holmium laser, that the concept of
channel patency, which has been our idea of this mechanism
over the last 8 years of work with the carbon dioxide laser,
seems to be confirmed in this study. Certainly that is the only
thing that I believe could explain the acute benefit. We are
doing a similar randomized study with the carbon dioxide
laser in a course of high-risk patients, 60% redo operations,
20% on preoperative intra-aortic balloon pump, that shows a
similar mortality benefit.
I have a few questions related to the presentation, and I
would like to first comment on how this nongraftable area
was determined in general. As you know, most vessels can
always be grafted. Whether they require an endarterectomy or
whether they are less desirable for bypass, of course, is anoth-
er issue. I wonder if any perfusion studies were done to
demonstrate lack of perfusion or poor perfusion in these areas
and viability and if that was of some assistance in determin-
ing the areas to be lazed.
The concept of ventricular perforation seems important. It
seems to me to be difficult to obtain information with regard
to perforation and whether perforation was achieved. I would
like for you to comment further how, without the use of the
echo, this was determined.
Because you have had experience with both of these
modalities, I would like further observations as to the use of
these modalities in the operative theater.
Dr Allen. Thank you, Dr Frazier, for those kind comments.
We owe a great deal to Dr Frazier’s pioneering work in this
area, and he is to be congratulated on the data that have come
out of his institution.
With regard to his first question regarding how nongrafted
areas were determined, no perfusion studies were used in this
study. Neither the Eclipse nor Atlantic trials, which are ran-
domized trials with a holmium laser as sole therapy com-
pared with medical management in patients with refractory
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angina not amenable to conventional surgery, were able to
demonstrate improved perfusion. The PLC carbon dioxide
laser (PLC Systems Inc, Milford, Mass) has demonstrated
weekly improved perfusion. We felt that it was not reasonable
to use perfusion in this type of a trial because of the difficul-
ty in separating the influence of bypass grafts versus TMR
channels. The areas that were determined to be ungrafted
were based on surgeon review of the angiogram and the intra-
operative evaluation of the vessels. As noted, a significant
number of patients (almost 10%) in this series required exten-
sive endarterectomies.
Now I will turn to your second question on how penetration
was confirmed without use of transesophgeal echocardiogra-
phy. The carbon dioxide laser requires a full ventricle to dis-
perse the collimated beam of energy that goes through in one
shot. The holmium:YAG laser is a pulsed laser that fires 5
pulses per second, and it takes about 5 to 8 pulses to traverse
the myocardium. With just a few cases, it is very easy on a
beating heart to learn the tactile and auditory sensation as to
when penetration takes place. When it is done on an arrested
heart, as was commonly done in this series, you obviously
lose that auditory sensation because the ventricle is not full
and beating, but the tactile sensation is still clearly there. In
addition, TEE is less helpful when a sternotomy is used
because the heart is lifted out of the pericardial cavity to reach
the lateral wall. It is very interesting that when you look at the
heart during retrograde perfusion after the laser channels have
been placed, there is perfuse bleeding from the laser channels.
Your final question was regarding comparisons of the
holmium carbon dioxide lasers. I gained experience with the
carbon dioxide laser during training in Dr Najafi’s program in
Chicago and have now used the holmium laser in over 200
patients at the Indiana Heart Institute in Indianapolis. In my
experience, both lasers are extremely efficacious and do a
very good job at meeting their end points. On the basis of
independent review by the FDA of both the PLC and Eclipse
randomized trials using TMR as sole therapy, there was not
any difference between the two modalities.
Dr Craig R. Smith (New York, NY). First, Dr Allen and his
coworkers are to be congratulated for being the first group to
demonstrate a nonsubjective benefit for TMR that occurs in
the first month. This is a surprising finding. I did not intend
to mention the experimental issues, but because we have been
subjected to the percutaneous myocardial revascularization
canine ventriculogram from Dr Oesterie, I feel I must point
out that there is no compelling experimental evidence of per-
fusion through these channels, which actually provides nutri-
tive blood flow to muscle, and I invite the audience to check
out the data. I acknowledge that this statement represents a
retraction of early data from my own laboratory published
about 6 years ago.
I grant that this study may show that there is acute perfu-
sion associated with channels occurring by some mechanism
that is unmasked in this setting, perhaps having to do with an
increase in global perfusion resulting from bypass grafts, and
this may in fact be an important contribution. However, let’s
look at some of the variables in this randomized study. 
The study was carried out in 24 centers. I think it is com-
mon in any center for two surgeons to disagree about the
graftability of a vessel. Consider just one scenario. A surgeon
evaluating a coronary branch, thought angiographically to be
nonbypassable, opens the vessel and finds it can indeed by
bypassed. Is that patient randomized or not? When is the
patient randomized? Is the region treated with laser or not?
This is just one example of multiple opportunities, in a study
design of this sort, for the strength of the surgeon’s belief in
the treatment to affect behavior. It is important for us to know
more about the details of the randomization: when did it
occur, were there patients withdrawn from the protocol, and
how many were withdrawn?
I am certainly prepared to be proven wrong by having these
findings confirmed in other trials, but the mortality benefit is
such a surprising finding that we need more assurance about
the study design.
Dr Allen. In answer to your first question, there is no doubt
that the mechanism of TMR is controversial. A commonly
quoted article from your institution, with Dr Burkhoff as
senior author, states that channels are not patent in the long-
term. Within the body of the article, however, it clearly states
that for 2 weeks microspheres traverse the channels when an
isolated heart model is used, showing that at least for a 2-
week period, acute channels are patent. In another common-
ly quoted article by Hardy, which also used microspheres and
concluded that channels were not patent, he clearly demon-
strated that channels were acutely patent for 5 days. They
may not stay open for very long, but they may stay open long
enough to give you some of the acute benefit that we
observed in this study.
With regard to your second question, when we statistically
looked at the results between the 24 centers, the centers did
not influence the results. Randomization was done before
surgery. Surgeons evaluated the angiogram, made a determi-
nation as to whether they thought they could completely
revascularize that patient, and then that patient was random-
ized. Three patients were withdrawn from the study as
detailed in the paper.
Dr Keith A. Horvath (Chicago, Ill). Nice presentation, Dr
Allen. I agree that the combination therapy provides a
method to achieve a more complete revascularization; how-
ever, the expected and observed mortality rates that you quote
for the patients undergoing CABG alone are somewhat high.
Having previously seen the demographics for your patients
and using those demographics and the relative risks from the
Society of Thoracic Surgeons (STS) database, a 2.3% mor-
tality rate is what would be predicted, and the surprising
result you are getting is not the 1.5% mortality rate with the
combined procedure but the 7.5% for CABG alone. This
7.5% mortality rate brings up the following question: would
those patients have been better served by being treated with
laser alone or even continuing their medical therapy because
both your work and that in other multi-institutional trials with
sole therapy with the laser have shown that the 30-day mor-
tality rate is less than 7.5% for those patients?
Echoing what Dr Smith has said, having evaluated a num-
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ber of these patients and approving them for combined pro-
cedures, we have a 40% rate of conversion from a preopera-
tive plan of CABG plus laser to CABG alone, because the
vessels were found intraoperatively to be graftable, and I have
to congratulate your cardiologists and surgeons for having a
100% agreement between the preoperative angiography and
the intraoperative findings.
Regarding the mechanism, there are no articles, even with
careful reading of the discussion sections, the bibliographies,
and the footnotes that demonstrate that using a holmium:YAG
laser creates patent channels with any substantial perfusion
benefit.
Dr Allen. Thank you for your comments, Dr Horvath. I
have heard them before when I presented the preliminary
findings of this study at the AHA last fall.
It is interesting that you were able to obtain STS mortality
data on the basis of the demographics presented at last year’s
AHA, because we certainly were not. All of the data points
that are needed to do an accurate STS mortality estimation
are not available for this study because they were not collect-
ed prospectively. Therefore if you put in left ventricular func-
tion, sex, and age, the STS database spits back “incomplete
data.” Therefore it is very interesting that you were able to do
it but we were not.
We were, however, able to prospectively collect the small-
er number of data points required for both Parsonnet and
O’Connor risk modeling, and what they showed was that a
higher operative mortality rate is expected in this popula-
tion, as was also alluded to by Dr Frazier. It is not unrea-
sonable in this population to expect the mortality rate that
we saw.
I think the other thing that is very important to emphasize
is that regardless of the predicted mortality rate, this is a
prospective randomized trial.
Dr Graeme L. Hammond (New Haven, Conn). Dr Allen,
this comment is to support your work and addresses the ques-
tion of function of channels that are created in the heart. Our
work carried out 28 years ago on the intact beating canine
heart and published in the American Journal of Physiology
clearly shows that under normal conditions little or no blood
enters the myocardium through pre-existing myocardial sinu-
soids left over from the phylogenetic development of the
mammalian heart. On the other hand, as ischemia progresses
and coronary flow and pressure decrease, 5% to 10% of
myocardial perfusion arises directly from the left ventricular
lumen, and this is under circumstances in which no channels
were created by the laser. Accordingly, I believe the physio-
logic setup is there and can be enhanced by the laser treat-
ment of the myocardium.
Dr Allen. Thank you for your comments. 
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